A string of venture capital firms have renewed their backing of biotech business Alios BioPharma to help it develop treatments for respiratory viral diseases.
Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures all took part in the $41m Series B round, which was led by a mystery investor.
SR One, the venture capital fund of pharmaceuticals giant GlaxoSmithKline, invested $8m in Alios in 2009 as part of a $32m financing round.
Alios president and CEO Lawrence Blatt said, “We are pleased to welcome our newest investor and to have the continued support from our current investors for this round of financing.
“This funding will allow Alios to retain ownership and control of our novel, first-in-class anti-respiratory virus development programs.”
Copyright © 2014 AltAssets